Not sure comparing it to Gilead is anything to rave about anymore after they cancelled their trial this morning ... people aren't rushing to try it ? I wonder what the reason is ?
Gilead shares slip as a 2nd remdesivir COVID-19 trial halted in China
by Ben Adams |
Apr 15, 2020 11:23am
(Gilead China) ShareFacebookTwitterLinkedInEmailPrint
After having to halt enrollment in its severe COVID-19 trial due to a lack of patients, a second test of Gilead’s old Ebola drug remdesivir has befallen the same fate, this time in patients with a milder form of the disease.
In an update via ClinicalTrials.gov posted today, the Gilead trial, being undertaken in China, is now registered as “Suspended (The epidemic of COVID-19 has been controlled well at present, no eligible patients can be recruited.”
Shares in the Big Biotech were down around 3% Wednesday morning on the news.
Even though Gilead has repeatedly stated this drug will not be the cornerstone of its pipeline future, many are betting it will be a consequential therapy for the company, especially if it managed to help patients suffering from the disease, given how widespread and desperate the need for any viable drug currently is.
Analyst Brian Abrahams from RBC said in a note to clients that it was still "50/50" if the drug could work.
This comes less than a week after a test for the drug in more severe cases of COVID-19 was also stopped due to poor enrollment.
SPL Price at posting:
$1.07 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)